Zepbound Costs Across Federal Programs, Compared

Last updated 3 weeks ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Across federal health programs, a Zepbound prescription can bring very different pharmacy bills. A posted figure may be a patient copay, a government purchase price or a conditional cash offer. These are not interchangeable prices.

Medicare’s temporary $50 copay, for example, is limited to eligible patients using the KwikPen. It does not price Zepbound vials or single-dose pens. Other programs can cover the medicine for one prescribed use but not another. The first question is whether each program covers the patient’s actual prescription; only then can its price be compared with an available cash offer.

The price on a program page is not always the patient’s price

The Food and Drug Administration’s Zepbound labeling covers weight reduction and long-term maintenance in qualifying adults and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The prescribed use matters because one program may pay for it and another may not. The TrumpRx KwikPen page asks a shopper to select the form, strength and fill period before seeing an offer. A price for a starting dose cannot stand in for the cost of a different strength or delivery device.

For Medicare’s glucagon-like peptide-1 (GLP-1) Bridge, the Centers for Medicare & Medicaid Services (CMS) reports a $245 monthly net price paid through the program and a separate $50 beneficiary copay. The first number describes the program’s acquisition arrangement; the second describes what an eligible person owes at the pharmacy. The Department of Veterans Affairs (VA) Federal Supply Schedule likewise contains negotiated government contract prices. Those prices are not a VA patient’s medication copay.

Lilly’s published regular self-pay prices are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg. Its terms define a month as 28 days and say the 2.5 mg dose is for treatment initiation rather than maintenance. The advertised starting figure is therefore not a safe estimate for every month of treatment.

Medicare: a $50 bridge, with narrow doors

CMS describes the Medicare GLP-1 Bridge as a temporary program running from July 1, 2026, through December 31, 2027. Medicare says its 2026 Bridge covers Zepbound KwikPen, not the single-dose vial or pen. Access is for people enrolled in qualifying Medicare drug coverage, including stand-alone Part D plans and Medicare Advantage plans with drug coverage. A Medicare card alone does not establish Bridge eligibility.

Medicare’s Bridge applies body-mass-index and health-condition criteria but excludes people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. A prescriber must send the prescription and complete prior authorization when requested; Medicare says beneficiaries can call 1-800-MEDICARE to check eligibility or authorization status. Ask the prescriber whether the prescription is for a Bridge-eligible use and product before comparing the $50 figure with cash offers.

The Bridge operates outside Part D’s ordinary payment flow, and its $50 copay does not count toward the Part D true out-of-pocket limit. Medicare also says a TrumpRx or other discount-card purchase made instead of using a Medicare plan does not count toward the Part D deductible or out-of-pocket maximum. A lower cash receipt can still leave a beneficiary farther from the plan’s annual spending limit. CMS calls the $245 a Bridge net price, not the amount a beneficiary pays and not an ordinary Part D claim.

Medicare says the prescriber must certify that the drug is used with a lifestyle program focused on diet and exercise. Its prior authorization can cover refills and dose changes through December 31, 2027, unless the beneficiary switches GLP-1 drugs. That authorization is a practical part of the price comparison: a pharmacy cannot deliver the Bridge copay for a claim the program has not approved.

CMS directs a Zepbound prescription for moderate-to-severe obstructive sleep apnea through ordinary Part D coverage, not the $50 Bridge, even if that drug is absent from the plan’s formulary. The Part D plan’s formulary-exception process remains available for that request. That can produce a very different patient bill from the Bridge, so the prescribed diagnosis matters as much as the brand name.

CMS says Zepbound KwikPen needles are not covered by the Medicare Bridge or Part D and must be bought separately. Ask the pharmacy to include the needle price when comparing the full cost of this route.

Medicaid: the state and plan decide

Federal Medicaid law makes outpatient prescription coverage optional, although all states provide it to categorically eligible people and most other enrollees. That broad drug benefit does not establish that a particular state’s plan covers Zepbound for a particular use. Medicaid’s State Prescription Drug Resources page links to state coverage and reimbursement methods. For a usable answer, ask the state Medicaid program or managed-care plan about the exact Zepbound formulation, indication, preferred status and prior authorization.

States may charge different copays for preferred and nonpreferred drugs; federal rules limit copays to nominal amounts for people at or below 150 percent of the federal poverty level. Manufacturer rebates are paid to states and shared with the federal government to offset Medicaid drug spending. A rebate that reduces public spending is not a quoted copay for the enrollee. CMS’s voluntary GENEROUS model aims to lower state net prices for participating drugs and may improve access in participating states. It does not create one national Zepbound copay.

Medicaid permits states to distinguish preferred from nonpreferred drugs and to set different copays for mail-order and retail pharmacies. The patient’s state, coverage arrangement and pharmacy can all matter, even before a drug rebate is considered. A state formulary or managed-care drug list is a better starting point than a national average, which cannot settle the person’s actual benefit.

VA, CHAMPVA and TRICARE follow different rules

In April 2026, VA Pharmacy Benefits Management Services and the National Formulary Committee issued criteria for using Zepbound for weight management. A veteran’s VA clinician must assess those criteria; a commercial advertisement is not an approval.

VA says some veterans are exempt from 2026 medication copays because of disability rating, income or other eligibility factors. For veterans who owe a copay, VA’s schedule lists $11 for up to 30 days of a tier-3 brand-name prescription and a $700 annual medication-copay cap. The schedule is a guide, not a verified Zepbound quote for every veteran; VA must confirm how the prescription is filled and charged.

TRICARE lists Zepbound for weight management under Prime, Select and several other plans when clinical criteria, a network prescription and prior authorization are met. TRICARE says that weight-loss-drug coverage does not apply to TRICARE For Life beneficiaries and points them to Medicare’s Bridge where eligible. TRICARE’s pharmacy table varies by military pharmacy, home delivery and retail network, with separate rules for active-duty service members and other beneficiaries. Before relying on a table amount, the beneficiary needs the drug’s current formulary tier and the applicable pharmacy route.

VA identifies its posted copay schedule as effective January 1, 2026. It lists $22 for a 31-to-60-day tier-3 brand-name supply and $33 for a 61-to-90-day supply. Those longer-supply figures should not be multiplied from a one-month cash offer: the supply, benefit and eligibility rules differ.

The Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) covers Zepbound for moderate-to-severe obstructive sleep apnea verified by a sleep study within the past 12 months. VA says CHAMPVA does not cover GLP-1 medications for weight loss and requires prior authorization for Zepbound. That is a family-member benefit, not the VA care and copay schedule for veterans described above.

When CHAMPVA is the only prescription coverage, its posted rules charge a $50 individual or $100 family annual deductible and then 25 percent of the allowable amount for covered retail prescriptions. Eligible CHAMPVA members without other prescription coverage may use Meds by Mail for a covered, non-urgent medicine with no out-of-pocket charge. Those are two ways of filling a covered prescription, not two prices a family can combine.

Federal worker and marketplace plans need a plan-specific quote

The Office of Personnel Management offers a 2026 Federal Employees Health Benefits plan-comparison page. The federal connection does not create a single Zepbound copay across those plans. Check the selected plan’s formulary and benefit brochure, then ask its pharmacy-benefit manager whether the prescribed formulation and use are covered.

HealthCare.gov says marketplace plans list covered drugs in a formulary and advises shoppers to check the insurer’s website, benefits summary or customer service. It also tells enrollees to check whether their regular pharmacy is in the plan’s network.

A marketplace deductible can apply to covered prescriptions, and an out-of-pocket maximum limits what a member spends on covered services. HealthCare.gov says TrumpRx offers operate outside marketplace coverage. A cash purchase should not be assumed to advance a plan deductible or annual maximum; the insurer must confirm whether and how it credits the purchase.

HealthCare.gov says a person whose plan does not cover a prescribed medicine can ask about the plan’s drug-exception process and appeal a denial. That route matters if the plan excludes a prescribed medicine; it does not guarantee approval or a particular copay. Ask the plan to price the exact drug and pharmacy after any authorization decision, not just to read a generic tier chart.

TrumpRx is a cash comparison, not another insurance plan

The TrumpRx KwikPen page advertises an out-of-pocket offer of up to 40 percent off and sends the shopper through LillyDirect for eligibility confirmation and purchase options. The separate vial page advertises up to 72 percent off and directs vial orders through LillyDirect. Those percentages are not a promise of the same dollar price for every strength or a promise that cash beats a copay. TrumpRx itself says an insured shopper’s copay may be lower than the displayed cash offer.

Medicare describes TrumpRx as a source of offers rather than a place to buy drugs directly, and says using its cash route instead of a Part D plan earns no Part D spending credit. HealthCare.gov likewise advises comparing the TrumpRx cash offer with the marketplace plan’s payment. The useful comparison is the final amount owed for the same dose and supply, plus what insurance spending the purchase will or will not count.

Lilly advertises a self-pay offer starting at $449 for a 28-day supply of higher-dose Zepbound KwikPen when its conditions are met. The regular $699 price for 10 mg through 15 mg may apply if the conditions are not met. That distinction is why a continuing-treatment quote needs both the dose and the refill terms.

For a Medicare beneficiary, the decisive fork is often whether the prescription can go through the Bridge, ordinary Part D coverage or a cash route; those payments are not interchangeable. For a Medicaid enrollee, VA patient or TRICARE beneficiary, the program’s own coverage and pharmacy rules come first. For a federal worker or marketplace enrollee, the plan and its pharmacy network supply the patient-specific amount.

Lilly describes the higher-dose offer as self-pay, not insurance, with automatic pricing through LillyDirect Pharmacy or a savings card for a retail KwikPen fill. A shopper must follow the route attached to the chosen form and confirm the offer’s eligibility terms before treating the advertised amount as a personal quote. Do not submit the same cash purchase as an insured fill or assume it counts toward a plan deductible.

Get the price for this prescription

Lilly says it can change or end its Zepbound self-pay offer without notice.

Medicare’s coverage page offers an eligibility questionnaire for people considering the GLP-1 Bridge.

First identify the prescribed indication, formulation, strength and quantity; a quote for a different Zepbound product answers a different question. Then ask the coverage program or plan whether it pays for that exact prescription, what authorization it requires, which pharmacy can fill it, and what the patient pays there. Compare that amount with the matching cash offer only after checking whether the cash purchase changes progress toward a deductible or out-of-pocket cap.

CMS says the Medicare Bridge is scheduled to end December 31, 2027. That date makes the Bridge page worth rechecking when a prescription is renewed near the program’s end. Medicaid keeps a state-by-state drug-coverage resource for changes in state methods. The lowest number on a website is useful only when it is available for the medicine the person will actually receive and the route they can actually use.